A team led by Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, examined plasma samples from 66 people with a mix of exposures to vaccines and variants. Some had received the bivalent booster distributed last fall, while others hadn’t, and each group included some people who had been recently infected by XBB.
The researchers made two key discoveries. The first is that everyone developed neutralizing antibodies against BA.2.86, and they were not any lower — and in fact were in most cases higher — than those generated against the already-circulating variants. In other words, the new variant does not seem to be as immune evasive as many had worried. “That was somewhat unexpected and welcome news,” Barouch says.
https://cvvr.hms.harvard.edu/wp-content/uploads/2023/09/WPOST.jpg 1080 1080 Sesedzayi Persesuh https://cvvr.hms.harvard.edu/wp-content/uploads/2020/03/cvvr-header-banner-long-white-bg.png Sesedzayi Persesuh2023-09-22 14:43:252023-09-22 14:48:24New Pirola Covid Variant Shows Value of Booster Shots